No Data
No Data
Shandong Boan Biotechnology Completes Share Placement
Boan Biotech (06955.HK) completed the distribution of a total of 26.66 million shares.
On August 7th, Gelunhui announced that the allotment matters have been completed on August 7th, 2024. A total of 26.66 million new shares (equivalent to about 4.97% of the total number of shares already issued after the issuance and distribution of shares) have been allotted and issued at a distribution price of HKD 9.50 per share to no less than six placing agents.
Shandong Boan Biotechnology Injection Gets FDA OK to Start US Clinical Trials
Bo'an Biotechnology (06955.HK): Dularity injection (BA5101) has been approved for clinical trials in the USA.
On August 5th, Gelunhui announced that the US Food and Drug Administration (FDA) has agreed to the company's self-developed Dulaglutide Injection ("BA5101") to conduct clinical trials in the United States. BA5101 is a biosimilar of Trulicity, which is intended for blood sugar control in type 2 diabetes patients. This product is the first Dulaglutide Injection produced by a Chinese company to be granted clinical trials in the United States. Previously, BA5101 was the first Trulicity biosimilar drug to be declared for listing in China, and its listing application was
Express News | Shandong Boan Biotechnology - Approval Obtained for Initiating Clinical Trials for Dulaglutide Injection (Ba5101) in U.S.
Boan Bio (06955.HK) plans to allocate 26.6556 million shares for a total of HKD 0.253 billion.
On July 31, Glory Hui announced that Boan Bioway (06955.HK) released an announcement about the subscription agreement with the company and the placing agents (UBS Group and AX Capital International) on July 30, 2024. Under the agreement, the placing agents agreed to act as the company's agents to encourage buyers to purchase the placing shares at the placing price according to individual benchmarks (not joint, nor common with the other placing agents) but subject to the terms and conditions of the subscription agreement. The total number of placing shares that may be sold under the placement is 26.6556 million shares, equivalent to approximately 5.23% of the total issued shares as of the date of this announcement; and
No Data